(February 1, 2013) -- Patent dispute settlements between brand-name and generic drug manufacturers that delay the time lower-cost medications reach the market are sharply rising, according to a recent Federal Trade Commission staff report. FTC chairman Jon Leibowitz has long decried these arrangements as “sweetheart deals.”...